Furthermore, combination therapy or the addition of PD-L1-binding moieties to the bispecific antibodies generated herein could enhance tumour cell-killing and avoid the upregulation of PD-L1 by MerTK in a potentially immunosuppressed TME. The gene discussed is CD274; the disease is neoplasm.